CEO Presentation to Include Updates and Further Information on the Following Topics: rd FREMONT, CA / ACCESS Newswire / January 26, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that the company's CEO will present at the 3 Annual DealFlow Discovery Conference, set to take place on January 28-29, 2026 in Atlantic City, New Jersey. Event Details Investors interested in scheduling a meeting with the Tivic's management team should request an investor ...

Core Insights - Tivic Health Systems, Inc. is set to provide a corporate update on its immunotherapeutic candidate Entolimod during the Emerging Growth Virtual Conference on January 21-22, 2026, highlighting recent advancements in manufacturing readiness [1][2] Company Developments - The CEO, Jennifer Ernst, will discuss the scale-up validation for Entolimod manufacturing and the vertical integration of Velocity Bioworks, which enhances in-house manufacturing capabilities and introduces new revenue streams [1] - The acquisition of Velocity Bioworks is expected to lower production costs, eliminate outsourcing delays, and accelerate the validation of current Good Manufacturing Practice (cGMP) for Entolimod [1] Product Information - Entolimod is a novel Toll-like Receptor 5 (TLR5) agonist that activates the NF-kappaB pathway, showing promising results in animal trials for Acute Radiation Syndrome (ARS), including improved survival rates and gastrointestinal recovery [5][6] - The drug is in late-stage development and aims to prevent cell death in bone marrow and epithelial tissues affected by radiation and age [6] Conference Details - The Emerging Growth Virtual Conference serves as a platform for public companies to present their innovations and major announcements to a broad audience of investors and analysts [3][4]

Tivic Health Systems Conference Summary Company Overview - **Company**: Tivic Health Systems (NasdaqCM:TIVC) - **Focus**: Development of non-invasive medical devices targeting neural pathways and a strong late-stage pipeline in biopharmaceuticals, particularly in immunomodulation and cancer therapeutics [1][2] Key Points Transformation and Pipeline Development - Tivic Health has undergone a significant transformation by acquiring newly licensed assets, leading to a robust late-stage portfolio in biopharmaceuticals [2] - The company maintains a clean capital structure with no debt and anticipates significant value inflection points in the near future [2] Biopharmaceutical Focus - The company is focusing on immunomodulation, utilizing the immune system to combat diseases and improve health outcomes [3] - A biologic licensing agreement was established, including a phase three recombinant protein funded by BARDA for radiation countermeasures, with potential applications in cancer [3][4] Entolimod and Market Opportunities - **Entolimod**: A TLR5 agonist with dual capabilities to treat acute radiation syndrome and cancer-related conditions, showing a 300% increase in survival rates with a single dose [9][23] - The market for GCSF drugs, which Entolimod aims to compete against, is valued at approximately $7.2 billion in 2023, with a broader neutropenia market of around $20 billion [9][31] - Entolimod is positioned as a military countermeasure for nuclear disasters, with a potential market opportunity of $5.2 billion for stockpiling [9][10] Clinical and Regulatory Progress - The company has made significant strides in customer engagement and manufacturing agreements, moving towards a Biologics License Application (BLA) filing [5][10] - The FDA has granted fast track and orphan drug designations for Entolimod, facilitating expedited regulatory processes [11] Future Directions and Strategic Focus - The company plans to focus on Entolimod over the next 6 to 18 months while also exploring other high-potential areas, including cancer therapeutics and vagus nerve stimulation technologies [17][35] - By 2026, Tivic Health aims to have GMP materials ready, FDA meetings completed, and customer interest solidified [34] Additional Insights - The company operates with a capital-light model and has a strong team with extensive experience in drug launches and biopharmaceutical development [16][25] - There is potential for partnerships with larger organizations to scale production and market reach effectively [29] - The vagus nerve technology remains a promising area for future development, with established research backing its efficacy [13][12] Conclusion Tivic Health Systems is positioned for growth with its innovative biopharmaceutical pipeline, particularly through Entolimod, which addresses significant market needs in radiation countermeasures and cancer therapeutics. The company's strategic focus on regulatory pathways and partnerships will be crucial for its success in the coming years.